) gained as much as 1.1% after it announced that SAFC Commercial,
its the custom manufacturing services business unit, has expanded
production at the Arklow facility in Ireland. The expansion at
the facility was done to produce new PharmaGrade products. The
company's shares eventually closed at $83.76 in the trading
session following the announcement, gaining around 0.7%.
AMER PAC CORP (APFC): Get Free Report
AMER VANGUARD (AVD): Free Stock Analysis
FERRO CORP (FOE): Free Stock Analysis Report
SIGMA ALDRICH (SIAL): Free Stock Analysis
To read this article on Zacks.com click here.
SAFC is now producing highly regulated active and non-active
pharmaceutical ingredients/raw materials at the Arklow facility,
which complements the raw materials production that started at
the site earlier this year.
SAFC selected Arklow facility for this expansion owing to its
specialized and highly regulated manufacturing capability. Each
and every PharmaGrade products offer high purity and they meet
and exceed the U.S. Food and Drug Administration (FDA)
regulations, follow Current Good Manufacturing Practices (cGMPs)
for biopharmaceutical production, adhere to International
Consortium for Innovation and Quality in Pharmaceutical
Development (IQ) requirements, and has consistently passed FDA
and Irish Medicines Board (IMB) inspections. PharmaGrade products
also follow ICH Q7 guidelines.
The new PharmaGrade products are built from difficult-to-source
materials developed from research to commercial-scale volumes.
SAFC utilized Arklow's purification, recrystallization and
distillation competencies to produce a short list of catalog
products in the PharmaGrade product line.
PharmaGrade product line includes benzyl alcohol, ethanolamine,
fumaric acid, N-acetyl-DL-tryptophan, sodium benzoate, sodium
butyrate and hexylene glycol products. These products started
their transition process to the Arklow facility in the fourth
quarter of 2011 and were upgraded to meet PharmaGrade guidelines
prior to production that commenced this year. SAFC also have
plans to expand its PharmaGrade product offering with the
expected launch of D-galactose in fourth-quarter 2013.
The PharmaGrade product line offers excellent quality of
products, which carry additive value of quality documentation
packages, readily-available inventory and multiple batches to
support the biopharma and pharma customer's qualification
Sigma-Aldrich is among the leading players in the specialty
chemical space along with
American Pacific Corp.
American Vanguard Corp.
). It is a leading life sciences and high technology company. It
develops, manufactures and distributes various biochemicals and
The SAFC Commercial unit is focused on biochemical production and
manufacturing of complex organic compounds. The division
manufactures and distributes bulk quantities of organic chemicals
and biochemicals used by pharmaceutical, biotechnology,
industrial, and diagnostic companies to develop and produce
Sigma-Aldrich carries a Zacks Rank #3 (Hold).
), with a Zacks Rank #1 (Strong Buy), is a good option for
investment in the specialty chemical industry.